EUVIMEDEUVIMED entdecken
Crossref

Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling

Yawen Yuan iD, Juan Wu, Jing Cao, Bulong Xu, Mei Zheng, Joseph F Standing iD

British Journal of Clinical Pharmacology · 10.11.2026

DOI: 10.1002/bcp.70915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.11.2026. Verfasst von Yawen Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to investigate the mechanisms and pharmacokinetic consequences of vincristine (VCR) drug–drug interactions (DDIs) with azole antifungals and dasatinib (DAS).

Methods

In vitro enzyme and transporter assays were conducted to characterize VCR metabolism and inhibition by posaconazole (POS), voriconazole (VRZ), fluconazole (FLZ) and DAS. Paediatric physiologically based pharmacokinetic (PBPK) models were developed using in vitro parameters and further refined using empirical Bayesian estimates from a VCR population pharmacokinetic model. Cytotoxicity was assessed using dorsal root ganglion (DRG) cell assays.

Results

POS competitively inhibited CYP3A4 and CYP3A5 ( Kᵢ = 1.62 and 1.35 μM) and P‐gp ( IC 50 = 7.72 μM), whereas VRZ competitively inhibited CYP3A4 and CYP3A5 ( Kᵢ = 8.87 and 4.22 μM) and additionally exhibited mechanism‐based inhibition of CYP3A4 (K I = 16.24 μM, k inact = 0.0263 min −1 ). FLZ showed weak inhibition of CYP3A4 and CYP3A5 (Kᵢ > 60 μM), whereas DAS showed moderate inhibition ( Kᵢ = 1.99–4.42 μM). The simulated VCR clearance was also approximately halved (CL = 0.59 vs . 0.33 L/h/kg) when co‐administrated with POS. Moreover, PBPK modelling indicated that intravenous POS and VRZ increased VCR AUCs by more than twofold. In vitro DRG cell assays demonstrated a concentration‐dependent potentiation of VCR‐induced cytotoxicity by POS.

Conclusions

Collectively, these PBPK model predictions suggest that POS and VRZ may represent high‐risk perpetrators of VCR DDIs in children and may help guide future dose optimization and toxicity management, pending confirmation in prospective clinical studies.

Schlagwörter

Stichwörter der Autor:innen

azole antifungals and dasatinibdrug–drug interactionphysiologically based pharmacokinetic modellingvincristinevincristine‐induced peripheral neuropathy

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Pharmaceutical Administration, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Infection, Immunity, Inflammation Section, UCL Institute of Child Health, London, UK.

ORCID-Profile: Yawen Yuan, Joseph F Standing

Förderung

  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Yuan, Y., Wu, J., Cao, J., Xu, B., Zheng, M., & Standing, J. F. (2026). Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70915

Vancouver

Yuan Y, Wu J, Cao J, Xu B, Zheng M, Standing JF. Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70915

BibTeX
@article{Yuan2026,
  author = {Yuan, Yawen and Wu, Juan and Cao, Jing and Xu, Bulong and Zheng, Mei and Standing, Joseph F},
  title = {Mechanistic insights into vincristine interactions with azoles and dasatinib: Implications for neurotoxicity in paediatric patients using physiologically based pharmacokinetic modelling},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70915}
}
Kostenlos starten →